GLUE
Monte Rosa Therapeutics Inc
10.30$
+1.5%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 21.1% | 178.3% | 43.9% | 22.8% | 3.4% | – | 9.2% | 16.4% | 75.1% | 48.2% | – | – | |
| – | -21.1% | -78.3% | 56.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 51.8% | 100.0% | 92.9% | |
| – | 310.0% | 2,361.7% | 553.7% | 299.7% | 64.1% | 37.9% | 132.2% | 287.3% | 1,509.5% | 1,046.8% | 534.8% | 594.2% | |
| – | 88.3% | 844.5% | 197.7% | 88.2% | 14.5% | 10.2% | 34.9% | 71.0% | 378.2% | 241.7% | 113.0% | 138.9% | |
| – | 398.3% | 3,206.2% | 751.4% | 387.8% | 78.6% | 48.1% | 167.1% | 358.3% | 1,887.7% | 1,240.3% | 647.8% | 726.0% | |
| – | -398.3% | -3,284.5% | -695.3% | -287.8% | 21.4% | 51.9% | -67.1% | -258.3% | -1,787.7% | -1,188.5% | -547.8% | -633.0% | |
| – | 10.7% | – | – | – | – | – | – | – | – | – | – | – | |
| – | -380.2% | -2,996.7% | -640.2% | -258.1% | 25.7% | 56.2% | -47.8% | -237.0% | -1,656.8% | -1,055.8% | -481.6% | -570.8% | |
| – | -0.3% | 7.8% | 5.4% | 0.8% | 3.6% | 1.0% | 5.2% | -24.9% | 2.1% | 1.2% | 2.3% | -9.9% | |
| – | -379.9% | -3,004.5% | -645.6% | -258.9% | 22.2% | 55.2% | -53.0% | -212.1% | -1,658.9% | -1,057.1% | -483.9% | -560.9% | |
| – | -359.1% | -2,818.4% | -596.3% | -235.3% | 29.1% | 58.6% | -38.7% | -220.6% | -1,581.7% | -1,007.6% | -460.2% | -542.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.